ZA804180B - Medicaments for the treatment of disorders in lipometabolism and their use - Google Patents

Medicaments for the treatment of disorders in lipometabolism and their use

Info

Publication number
ZA804180B
ZA804180B ZA00804180A ZA804180A ZA804180B ZA 804180 B ZA804180 B ZA 804180B ZA 00804180 A ZA00804180 A ZA 00804180A ZA 804180 A ZA804180 A ZA 804180A ZA 804180 B ZA804180 B ZA 804180B
Authority
ZA
South Africa
Prior art keywords
lipometabolism
medicaments
disorders
treatment
Prior art date
Application number
ZA00804180A
Other languages
English (en)
Inventor
H Krause
E Klauke
M Mardin
H Kabbe
R Sitt
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA804180B publication Critical patent/ZA804180B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA00804180A 1979-07-14 1980-07-11 Medicaments for the treatment of disorders in lipometabolism and their use ZA804180B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792928485 DE2928485A1 (de) 1979-07-14 1979-07-14 Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen

Publications (1)

Publication Number Publication Date
ZA804180B true ZA804180B (en) 1981-07-29

Family

ID=6075715

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA00804180A ZA804180B (en) 1979-07-14 1980-07-11 Medicaments for the treatment of disorders in lipometabolism and their use

Country Status (10)

Country Link
US (1) US4405644A (no)
EP (1) EP0022958A1 (no)
JP (1) JPS5616411A (no)
AU (1) AU544252B2 (no)
DE (1) DE2928485A1 (no)
DK (1) DK302480A (no)
ES (1) ES493327A0 (no)
IL (1) IL60555A0 (no)
NO (1) NO151362C (no)
ZA (1) ZA804180B (no)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL67417A (en) * 1982-01-26 1989-10-31 American Cyanamid Co Antiatherosclerotic substituted ureas,process for their preparation and pharmaceutical compositions containing them
US4623662A (en) 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
US5003106A (en) * 1983-07-19 1991-03-26 American Cyanamid Company Antiatherosclerotic ureas and thioureas
IE57775B1 (en) * 1983-08-22 1993-04-07 Warner Lambert Co N-(2,6-disubstituted aromatic)-n'-pyridinyl ureas,processes for their production and pharmaceutical compositions comprising the same
US4689348A (en) * 1984-08-17 1987-08-25 Dow Chemical Company Cyanoguanidines useful as animal growth promoting agents
US4661520A (en) * 1984-08-17 1987-04-28 The Dow Chemical Company Cyanoguanidine useful as an animal growth promoting agent
DE3636190A1 (de) * 1986-10-24 1988-04-28 Bayer Ag Verfahren zur herstellung von n,n-diaryl-harnstoffen
CN1021819C (zh) * 1988-01-20 1993-08-18 山之内制药株式会社 作为药物有用的双脲衍生物的制备方法
US5290814A (en) * 1988-11-21 1994-03-01 Burroughs Wellcome Co. Anti-atherosclerotic diaryl compounds
JPH0395153A (ja) * 1989-06-15 1991-04-19 Mitsubishi Kasei Corp ジフェニル尿素誘導体
EP0425443A1 (de) * 1989-10-27 1991-05-02 Ciba-Geigy Ag Injizierbares parasitizides Mittel
JPH05310678A (ja) * 1990-01-22 1993-11-22 Mitsubishi Kasei Corp １−フェニルアルキル−３−フェニル尿素誘導体
DE69105786T2 (de) * 1990-03-12 1995-04-27 Yamanouchi Pharma Co Ltd Harnstoffderivate, deren Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen.
US5258405A (en) * 1990-03-12 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Urea derivatives and salts thereof in method for inhibiting the ACAT enzyme
US5162360A (en) * 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
JPH11503110A (ja) 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
SK286662B6 (sk) 1996-04-23 2009-03-05 Vertex Pharmaceuticals Incorporated Deriváty močoviny, farmaceutické prostriedky, ktoré ich obsahujú, a ich použitie ako inhibítorov aktivity IMPDH enzýmu
DE69716424T2 (de) * 1996-05-24 2003-02-20 Neurosearch A/S, Ballerup Saure gruppen enthaltende phenylderivate, ihre herstellung und ihre verwendung als chloridkanalblocker
AU3409197A (en) * 1996-06-27 1998-01-14 Smithkline Beecham Corporation Il-8 receptor antagonists
PL330849A1 (en) 1996-06-27 1999-06-07 Smithkline Beecham Corp Antagonists of il-8 receptors
EP0957907A4 (en) 1996-08-06 2001-08-16 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US6177448B1 (en) 1996-08-06 2001-01-23 Smithkline Beecham Corporation IL-8 receptor antagonists
WO1998040381A1 (en) 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US6696475B2 (en) 1997-04-22 2004-02-24 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US6344476B1 (en) * 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
JP3887769B2 (ja) * 1997-12-22 2007-02-28 バイエル コーポレイション 対称および非対称ジフェニル尿素を用いるｐ３８キナーゼの阻害
AP2001002103A0 (en) * 1998-10-22 2001-03-31 Neurosearch As Substituted phenyl derivatives, their preparation and use.
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UY26207A1 (es) * 1999-06-16 2000-12-29 Smithkline Beecham Corp Antagonistas de los receptores de la il-8.
JP4773010B2 (ja) 1999-06-25 2011-09-14 バーテックス ファーマシューティカルズ インコーポレイテッド Ｉｍｐｄｈのカーバメート阻害剤のプロドラッグ
MXPA02002578A (es) 1999-09-08 2002-10-23 Guilford Pharm Inc Compuestos de union a ciclofilina no peptidicos, y su uso.
US7105567B2 (en) * 2000-08-10 2006-09-12 Mitsubishi Pharma Corporation 3-substituted urea derivatives and medicinal use thereof
US6894063B2 (en) 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
US6946476B2 (en) * 2000-12-21 2005-09-20 Schering Corporation Heteroaryl urea neuropeptide Y Y5 receptor antagonists
AR035520A1 (es) * 2000-12-21 2004-06-02 Schering Corp Compuestos heteroarilo urea que son neuropeptidos y antagonistas de los receptores y5 del neuropeptido y, composiciones farmaceuticas, un proceso para su preparacion, uso de dichos compuestos y composiciones para la manufactura de medicamentos
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2435829A1 (en) 2001-01-25 2002-08-01 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
DE10109204A1 (de) * 2001-02-26 2002-09-19 4Sc Ag Verbindungen zur Behandlung von Protozoen-Erkrankungen
US6949567B2 (en) 2001-02-26 2005-09-27 4Sc Ag Compounds for the treatment of protozoal diseases
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
PE20030385A1 (es) 2001-07-26 2003-05-08 Schering Corp Compuestos de urea como antagonistas de receptores y5 del neuropeptido y
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT2305255E (pt) * 2001-12-03 2012-09-04 Bayer Healthcare Llc Compostos de arilureia em combinação com outros agentes citostáticos ou citotóxicos para tratamento de cancros humanos
AU2002351748B2 (en) * 2001-12-21 2009-07-09 Novo Nordisk A/S Amide derivatives as GK activators
AU2003209119A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
AU2003210969A1 (en) * 2002-02-11 2003-09-04 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
DK1580188T3 (da) * 2002-02-11 2012-02-06 Bayer Healthcare Llc Forbindelser af arylurea som kinaseinhibitorer
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
WO2004002481A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
CN1678608A (zh) 2002-07-02 2005-10-05 先灵公司 新的神经肽yy5受体拮抗剂
US7056925B2 (en) * 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
JP4244288B2 (ja) * 2002-08-29 2009-03-25 フジノン株式会社 ３群ズームレンズ
MY143477A (en) * 2002-10-29 2011-05-31 Smithkline Beecham Corp Il-8 receptor antagonists
CA2502705A1 (en) * 2002-11-21 2004-06-03 Jon Valgeirsson Aryl ureido derivatives and their medical use
US20060229335A1 (en) * 2002-12-24 2006-10-12 Bradley Teegarden Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
MXPA05007513A (es) * 2003-01-14 2005-09-21 Cytokinetics Inc Compuestos, composiciones y metodos.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
ATE313532T1 (de) * 2003-07-22 2006-01-15 Arena Pharm Inc Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
ME00294B (me) 2003-07-23 2011-05-10 Bayer Pharmaceuticals Corp Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti
JP4765627B2 (ja) 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
CN1926114B (zh) * 2004-03-23 2011-08-24 艾尼纳制药公司 用于制备经取代n-芳基-n′-′3-(1h-吡唑-5-基)苯基脲及其中间体的方法
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
CA2564325A1 (en) * 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
SA05260357B1 (ar) * 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
MX2007005137A (es) * 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
US20080015223A1 (en) * 2004-12-03 2008-01-17 Arena Pharmaceuticals, Inc. Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
CN101160127A (zh) * 2005-01-19 2008-04-09 艾尼纳制药公司 用于预防或治疗进行性多灶性白质脑病而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
JP2009500378A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
US7884210B2 (en) * 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
JPWO2007024004A1 (ja) 2005-08-24 2009-03-05 萬有製薬株式会社 フェニルピリドン誘導体
WO2007022964A2 (de) 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
CA2625416A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHIIN DERIVATIVES
US8158791B2 (en) 2005-11-10 2012-04-17 Msd K.K. Aza-substituted spiro derivatives
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
RU2008145871A (ru) * 2006-04-21 2010-05-27 Смитклайн Бичам Корпорейшн (US) Антагонисты рецептора il-8
PL2009992T3 (pl) * 2006-04-21 2012-11-30 Glaxosmithkline Llc Antagoniści receptora IL-8
USRE45336E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
MX2008014622A (es) 2006-05-18 2008-11-28 Arena Pharm Inc Formas cristalinas y procesos para la preparacion de fenil-pirazoles utiles como moduladores del receptor de serotonina 5-ht2a.
CA2646076C (en) * 2006-05-18 2015-06-30 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
TW200817006A (en) * 2006-06-23 2008-04-16 Smithkline Beecham Corp IL-8 receptor antagonist
EP2066642A1 (en) * 2006-09-25 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
AU2007299992A1 (en) * 2006-09-28 2008-04-03 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
CA2664358A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diarylketimine derivative
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
CL2007002958A1 (es) * 2006-10-12 2008-05-09 Epix Delaware Inc Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
WO2008051875A2 (en) * 2006-10-20 2008-05-02 Arete Therapeutics, Inc. Adamantylurea compounds as soluble epoxide hydrolase inhibitors
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US20100144736A1 (en) * 2006-12-18 2010-06-10 Neurosearch A/S Novel biphenyl thio-urea derivatives useful as potassium channel modulators
JP2010515701A (ja) * 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
JP5226008B2 (ja) 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2421237T7 (es) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
WO2009035951A2 (en) * 2007-09-11 2009-03-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
US20100331298A1 (en) * 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
AU2008335135A1 (en) 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
AU2009277736A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
ES2666324T3 (es) 2008-10-28 2018-05-04 Arena Pharmaceuticals, Inc. Composiciones de un modulador del receptor de serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con el mismo
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
NZ597379A (en) 2009-06-29 2014-04-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
EP2491145B1 (en) 2009-10-21 2016-03-09 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20130072519A1 (en) 2010-05-21 2013-03-21 Edward Lee Conn 2-phenyl benzoylamides
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8796258B2 (en) 2011-02-25 2014-08-05 Merck Sharp & Dohme Corp. Cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2680874A2 (en) 2011-03-04 2014-01-08 Pfizer Inc Edn3-like peptides and uses thereof
CN108451955B (zh) 2011-05-03 2022-02-01 安吉奥斯医药品有限公司 用于治疗的丙酮酸激酶活化剂
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103159686A (zh) * 2011-12-09 2013-06-19 天津市国际生物医药联合研究院 一种hiv-1蛋白酶的脲类抑制剂
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10202339B2 (en) 2012-10-15 2019-02-12 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
JP6529492B2 (ja) 2013-07-11 2019-06-12 アジオス ファーマシューティカルズ， インコーポレイテッド 癌の処置のためのｉｄｈ２突然変異体阻害剤としての２，４−または４，６−ジアミノピリミジン化合物
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
GB201404372D0 (en) * 2014-03-12 2014-04-23 Univ Warwick Assay and treatment
KR20240010105A (ko) 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
DK3186242T3 (da) 2014-08-29 2021-12-20 Tes Pharma S R L Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
PL3307271T3 (pl) 2015-06-11 2024-02-05 Agios Pharmaceuticals, Inc. Sposoby stosowania aktywatorów kinazy pirogronianowej
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
EP3362065B1 (en) 2015-10-15 2024-04-03 Les Laboratoires Servier Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
AU2016338557B2 (en) 2015-10-15 2022-05-26 Celgene Corporation Combination therapy for treating malignancies
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
MX2020008905A (es) 2018-06-12 2020-12-03 Vtv Therapeutics Llc Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN113574055B (zh) 2019-01-18 2024-07-23 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
CZ2020559A3 (cs) * 2020-10-13 2022-04-27 Ústav experimentální botaniky AV ČR, v. v. i. Látky pro rostlinné biotechnologie na bázi 1-fenyl-3-yl-močoviny, přípravky je obsahující a jejich použití
CN115804844B (zh) * 2022-09-26 2024-05-10 郑州大学 靶向抑制pak4的抑制剂在制备肿瘤防治药剂中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE924864C (de) * 1950-11-12 1955-04-21 Hoechst Ag Verfahren zur Herstellung von Thioharnstoffabkoemmlingen
DE859151C (de) * 1951-03-09 1952-12-11 Gruenenthal Chemie Verfahren zur Herstellung des symm. Di-[2-oxy-carboxyphenyl-(4)]-thioharnstoffs
FR1063842A (fr) * 1951-05-28 1954-05-07 Ciba Geigy Procédé de préparation de nouvelles bis-phényl-thiourées
FR1067900A (fr) * 1951-07-20 1954-06-21 Ciba Geigy Procédé pour la préparation de nouvelles bis-phényl-thiourées
FR1073588A (fr) * 1952-01-28 1954-09-27 Ciba Geigy Procédé pour la préparation de nouvelles diphényl-thiourées substituées
FR1078457A (fr) * 1952-01-31 1954-11-18 Ciba Geigy Procédé de préparation de nouvelles diphényl-thiourées substituées
US2688039A (en) * 1952-02-08 1954-08-31 Ciba Pharm Prod Inc Halogen-containing di-(substituted phenyl)-thioureas
FR1080728A (fr) * 1952-05-02 1954-12-13 Ciba Geigy Procédé de préparation de nouvelles diphénylthiourées substituées
DE962699C (de) * 1953-04-26 1957-04-25 Schering Ag Verfahren zur Herstellung choleretisch wirksamer N-Acylderivate der 2, 4, 6-Trijod-3-amino-benzoesaeure
US2745874A (en) * 1953-06-18 1956-05-15 Geigy Ag J R Insecticidal derivatives of diphenyl urea
CH322815A (de) * 1954-03-09 1957-06-30 Wander Ag Dr A Verfahren zur Darstellung von N,N'-(4,4'-Dicarboxy-3,3'-dioxy)-diphenyl-harnstoff und dessen Salzen
US2983646A (en) * 1958-04-10 1961-05-09 Monsanto Chemicals Anthelmintic compositions containing substituted carbanilides and methods of using same
NL254871A (no) * 1959-08-14
DE1221638B (de) * 1960-07-22 1966-07-28 Hoechst Ag Verfahren zur Herstellung von Thioharnstoffen
US3340145A (en) * 1961-04-21 1967-09-05 Ciba Geigy Corp Carbanilide compositions and methods of using same
FR2104M (fr) * 1962-01-26 1963-10-28 Madan Ag Thiocarbanilides a propriétés anti inflammatoires et antifongiques.
FR3361M (fr) * 1962-04-02 1965-06-08 Ciba Geigy Nouveau médicament anthelmintique.
US3200035A (en) * 1962-06-01 1965-08-10 Ciba Ltd Treatment of synthetic products, especially synthetic fibers
GB969808A (en) * 1962-06-08 1964-09-16 Boots Pure Drug Co Ltd Anthelmintic compositions and compounds
GB1055741A (en) * 1963-07-12 1967-01-18 Ici Ltd Pharmaceutical compositions comprising substituted urea derivatives
GB1059034A (en) * 1964-01-16 1967-02-15 Ici Ltd Urea derivatives
US3335142A (en) * 1965-07-07 1967-08-08 American Cyanamid Co Process for the preparation of n, n'-disubstituted ureas
SE370866B (no) * 1968-03-21 1974-11-04 Ciba Geigy Ag
GB1219698A (en) * 1969-10-22 1971-01-20 Givaudan & Cie Sa Substituted carbanilides and their use
US3856952A (en) * 1973-03-01 1974-12-24 Pennwalt Corp Synergistic antimicrobial compositions employing certain n-(phenyl-carbamyl)amino-benzene sulfonyl flourides
DE2311020A1 (de) * 1973-03-06 1974-09-12 Pfizer Substituierte benzoesaeuren und arzneimittel
US3860645A (en) * 1973-05-23 1975-01-14 Givaudan Corp Bacteriostatic substituted carbanilides
US3903130A (en) * 1974-05-03 1975-09-02 Stauffer Chemical Co 1-Trifluormethylphenyl-3-dicyanophenyl urea
US4011340A (en) * 1975-05-08 1977-03-08 Sandoz, Inc. Hypolipidemic bis(pivaloylbenzyl) ureas

Also Published As

Publication number Publication date
DK302480A (da) 1981-01-15
AU6019480A (en) 1981-01-15
AU544252B2 (en) 1985-05-23
JPS5616411A (en) 1981-02-17
NO801965L (no) 1981-01-15
ES8105292A1 (es) 1981-05-16
ES493327A0 (es) 1981-05-16
US4405644A (en) 1983-09-20
NO151362C (no) 1985-03-27
IL60555A0 (en) 1980-09-16
EP0022958A1 (de) 1981-01-28
DE2928485A1 (de) 1981-01-29
NO151362B (no) 1984-12-17

Similar Documents

Publication Publication Date Title
ZA804180B (en) Medicaments for the treatment of disorders in lipometabolism and their use
ZA791728B (en) Cerebral therapeutic agent and its use
JPS5643217A (en) Water drug for external application for trauma treatment and manufacture thereof
JPS5692816A (en) Prescription of long controlled effect belnded medicine and its composition
GB2013495A (en) Therapeutic method for the treatment of hyperlipodaemias and hyperlipoproteinaemias
EP0204597A3 (en) Use of alfuzosine in the treatment of urinary affections
ZM6780A1 (en) Preparations for the treatment of theileriosis and their use
JPS5615250A (en) Aminoether type oxide* its manufacture and therapeutic use
GB2063668B (en) Beta-cyclodextrin for use in the treatment of acne
DE3062981D1 (en) Alkyl-urea derivatives for the treatment of lipometabolic diseases; process for their preparation, their use in medicaments for the treatment of lipometabolic disorders, medicaments containing them, process for the preparation of the medicaments, and some alkyl-urea derivatives
HK36693A (en) Use of ketone derivatives in the treatment of cognitive disorders
HU178841B (en) Cattle-leader for the prophylactic or therapeutic treatment of cattle
JPS5622716A (en) Hair treatment product and its manufacture
GB2071091B (en) Acyl-derivatives of carnitine and the therapeutic use thereof
ZA796882B (en) Use of glycerylphosphoryl derivatives in the therapy of dislipaemia,hepatitis and like pathological conditions and pharmaceutical compositions therefor
GB2098478B (en) Propioibacteria preparations for use in the treatment of tumours
AU530790B2 (en) Triazinones and their use in treating gastrointestinal disorders
IL59764A0 (en) Drug on the basis of dihydroergo-toxine and procedure for its manufacture
GB1546034A (en) Therapeutic compositions and the use thereof
PH16250A (en) Pharmaceutical composition of therapeutic value in the treatment of some shock conditions
DE3362340D1 (en) A pharmaceutical composition and the use thereof for the treatment of inflammation
DE3264378D1 (en) Medicaments for the treatment of obesity and hyperlipoidemia
EG14024A (en) Pharmaceutical compositions and their use in the profyloxis and or treatment of certain diseases
GB2048250B (en) 2-amino-6-aryl-4-pyrimidinols and their pharmaceutical uses
EP0059346A3 (en) Therapeutic agent and the use thereof